Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Breast 1

Conditions

Breast Neoplasms 2Biliary Tract Neoplasms 2Adenocarcinoma Of Esophagus 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Hemangiosarcoma 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Advanced Malignancies 1

Interventions

Oxaliplatin 8Fluorouracil 8Nivolumab 7Leucovorin 7Paclitaxel 6Capecitabine 5Taxes 4Specimen Handling 4pembrolizumab 3Trastuzumab 3Ramucirumab 3Magnetic Resonance Spectroscopy 3Cisplatin 3zimberelimab 2zanidatamab 2Radiotherapy 2Folfox protocol 2Carboplatin 2zolbetuximab 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1tislelizumab 1quemliclustat 1obeticholic acid 1futibatinib 1dehydroftorafur 1cixutumumab 1balstilimab 1Saline Solution 1Radiofrequency Ablation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × zanidatamab × 30 days × Clear all
NCT06324357 2026-05-26

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Boehringer Ingelheim

Phase 1/2 Recruiting
768 enrolled
BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

NCT05152147 2026-05-19

HERIZON-GEA-01

Jazz Pharmaceuticals

Phase 3 Active not recruiting
920 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡